Search

Displaying results 3671 - 3680 of 7479 in total
  1. Drug

    Nesvategrast

    go.drugbank.com/drugs/DB19337
    Investigational

    Nesvategrast is under investigation in clinical trial NCT05409235 (Nesvategrast (OTT166) in Diabetic Retinopathy (DR)).

  2. Drug

    Leptin

    go.drugbank.com/drugs/DB05098
    Investigational

    Although leptin is a circulating signal that reduces appetite, in general, obese people have an unusually high circulating concentration of leptin.

  3. Drug

    Plozalizumab

    go.drugbank.com/drugs/DB12520
    Investigational

    Preclinical studies suggest that CCR2 plays an important role in the trafficking of monocytes and macrophages to sites of inflammation.

  4. Drug

    Sotalol

    go.drugbank.com/drugs/DB00489
    ApprovedInvestigational

    [A178579] Sotalol was first approved as an oral tablet on 30 October 1992.

    International brands: Tan Shi, Xi An Lin
  5. Drug

    Tropicamide

    go.drugbank.com/drugs/DB00809
    Approved

    Tropicamide is an alkaloid atropine‐derived anticholinergic drug and a non‐selective antagonist of muscarinic acetylcholine (mACh) receptors.

  6. Drug

    Lubiprostone

    go.drugbank.com/drugs/DB01046
    ApprovedInvestigational

    Lubiprostone is a medication used in the management of idiopathic chronic constipation. A prostaglandin E1 derivative, lubiprostone is a bicyclic fatty acid that activates ClC-2 chloride channels located on the apical side of the gastroi...

  7. Drug

    Squalene

    go.drugbank.com/drugs/DB11460
    ApprovedInvestigationalVet approvedWithdrawn

    Squalene is investigated as an adjunctive cancer therapy.

  8. Drug

    Miocamycin

    go.drugbank.com/drugs/DB13287
    Approved

    shown to be effective against several gram-positive and gram-negative microbes and may be useful in the treatment of upper and lower respiratory tract infections, and urogenital tract infections or as an

  9. Drug

    FG-2216

    go.drugbank.com/drugs/DB08687
    Investigational

    A orally active prolyl-hydroxylase inhibitor which can stabilize hypoxia-inducible transcription factor independent of oxygen availability. [A14422]

  10. Drug

    Pumactant

    go.drugbank.com/drugs/DB04955
    Experimental

    Pumactant is a synthetic surfactant used for treating respiratory distress syndrome in neonates. It is a unique formulation of the naturally occurring phospholipids Dipalmitoylphosphatidycholine (DPPC) and Phosphatidyl Glycerol (PG).